Stem Cell Clinic – Page 833

COVID-19: Responding to the business impacts of Rise in expanse of applications boosts Rheumatoid Arthritis Stem Cell Therapy market 2018 to 2028 3w…

By adminMay 9, 2020Stem Cell Treatment

Companies in the Rheumatoid Arthritis Stem Cell Therapy market are facing issues in keeping their production facilities fully functional due to shortage of staff and resources amidst the COVID-19 (Coronavirus) outbreak. Get a hands-on over key drivers and threats to the Rheumatoid Arthritis Stem Cell Therapy market to make your company future-ready post the pandemic. Avails out reports for exciting prices to learn new opportunities that companies can capitalize on during and after the Coronavirus crisis.

Latest Insights on the Global Rheumatoid Arthritis Stem Cell Therapy Market

According to the analysis of the research analysts at Fact.MR, the Rheumatoid Arthritis Stem Cell Therapy market is set to reach a market value of ~US$XX by the end of 20XX. Further, the study indicates that the Rheumatoid Arthritis Stem Cell Therapy market is expected to grow at a CAGR of ~XX% during the forecast period (20XX-20XX). The well-researched market report offers a thorough quantitative and qualitative assessment of the Rheumatoid Arthritis Stem Cell Therapy market along with easy to grasp tables, graphs, and figures.

The market study bifurcates the global Rheumatoid Arthritis Stem Cell Therapy market in different segments to enhance the reading experience of our clients.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

The various segments covered in the report are as follows.

Competitive outlook

The competitive outlook tracks the business proceeding of top-tier market players involved in the Rheumatoid Arthritis Stem Cell Therapy market. The company profile provides a clear understanding of the growth strategies adopted by various market players.

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Key takeaways from the presented market analysis:

The market analysis provides answers to some important questions related to the Rheumatoid Arthritis Stem Cell Therapy market:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Reasons to Opt for Fact.MR

Excerpt from:
COVID-19: Responding to the business impacts of Rise in expanse of applications boosts Rheumatoid Arthritis Stem Cell Therapy market 2018 to 2028 3w...

Cell Therapy Market 2020 by Various Types, End-Use Application, Major Players, Forecast 2025 – Cole of Duty

By adminMay 9, 2020Stem Cell Treatment

The Global Cell Therapy Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally.

Leading Companies Reviewed in the Report are:

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Get Sample Copy of this Report @ https://www.adroitmarketresearch.com/contacts/request-sample/611

This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Cell Therapy market Report offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The research report on the global Cell Therapy market includes certain segments by type & application, region and major players. Each type offers data about the production during the slated period of 2015 to 2026. Whereas, the application segment also delivers consumption during the predicted timeframe of 2015-2026. Understanding the segments helps in recognizing the importance of distinct elements that aid the growth of the Cell Therapy market globally. Additionally, it provides in-depth analysis of growth rate and other factors of the global Cell Therapy market in pivotal regions.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market

Global Cell Therapy Market is segmented based by type, application and region.

Based on Type, the Market has been segmented into:

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

The report provides a thorough assessment of the growth and other aspects of the Cell Therapy market in key regions, including the United States, Canada, Italy, Russia, China, Japan, Germany, and the United Kingdom United Kingdom, South Korea, France, Taiwan, Southeast Asia, Mexico, India and Brazil, etc. The main regions covered by the report are North America, Europe, the Asia-Pacific region and Latin America.

The research report on the world Cell Therapy market has been designed briefly by observing and examining various aspects that discover regional growth of the specific industry. Our analysts team has examined the production cost, revenue data, production, import/export details and key manufacturers of each region. It also evaluates region-wise volume and revenue for the forecast time period between 2020 to 2026. These investigations will help the reader to clearly understand the potential worth of expenditure in a specific region.

For Any Query on the Cell Therapy Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Go here to read the rest:
Cell Therapy Market 2020 by Various Types, End-Use Application, Major Players, Forecast 2025 - Cole of Duty

Global Stem Cell Therapy Market 2020 With COVID-19 Update by Development factors analysis, Competitive Strategies and Forecast to 2025 – Bandera…

By adminMay 9, 2020Stem Cell Treatment

GlobalStem Cell TherapyMarket Report 2020, Forecast to 2025presents a historical overview of market size, revenue, share, forecast, and market drivers. The report features detailed insights and deep research on the globalStem Cell Therapymarket. The report studies various segments, as well as key opportunities in the market and influencing factors which will help businesses increase their footprints in the industry. A comprehensive analysis of the product scope and market risks has been given for the participants. The report shows the company profile of the major vendors along with their winning strategies to give business owners, stakeholders, and field marketing personal a competitive edge over others operating in the market.

Get Free Sample Report:https://www.magnifierresearch.com/report-detail/36202/request-sample

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

The Market Report Addresses:

The report provides historical and forecasts market data including demand, application details, price trends, and company shares of the leading manufacturers by geography, and estimation of the globalStem Cell Therapymarket size by volume and value. The growth estimation of the market is offered on the basis of calculation by various segmentation and past and current data. This market has been divided into types, applications, and regions. The report also covers the growth aspects of the market along with the restraining factors which are expected to impact the overall growth of the market in the estimated forecast period from 2020 to 2025.

The top manufacturers/suppliers which are currently operating in the globalStem Cell Therapymarket industry includes:Mesoblast, Regeneus, U.S. Stem Cell

By the product type, the market is primarily split into:Monotherapy, Combination Therapy

By the end-users/application, this report covers the following segments:Osteoarthritis (unspecified), Knee Osteoarthritis, Shoulder Osteoarthritis, Hip Osteoarthritis

Market Regions and Countries Level Analysis:

Regional analysis is a highly comprehensive section of this report. This segmentation sheds light on the sales of theStem Cell Therapyon regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market. Market segmented by region/country:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Access Full Report:https://www.magnifierresearch.com/report/global-stem-cell-therapy-market-report-2020-forecast-36202.html

Moreover, the report aims to deliver evaluation and essential information on the competitive landscape to meet the unique requirements of the companies and individuals operating in the market. The study recognizes the factors affecting the globalStem Cell Therapymarket growth such as drivers, restraints, opportunities, and trends. The report also recognizes emerging players with a potentially strong product portfolio and creates effective counter-strategies to gain competitive advantage. The report features reliable high-quality data and analysis which is suitable for supporting your internal and external presentations. The market research report will also help create regional and country strategies on the basis of local data and analysis.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@magnifierresearch.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@magnifierresearch.comWeb:www.magnifierresearch.com

Link:
Global Stem Cell Therapy Market 2020 With COVID-19 Update by Development factors analysis, Competitive Strategies and Forecast to 2025 - Bandera...

Induced Pluripotent Stem Cells (iPSCs) Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 – Cole of Duty

By adminMay 9, 2020Induced Pluripotent Stem Cells

Reprocell

The scope of the Report:

The report analyzes the key opportunities, CAGR, and Y-o-Y growth rates to allow readers to understand all the qualitative and quantitative aspects of the Induced Pluripotent Stem Cells (iPSCs) market. A competition analysis is imperative in the Induced Pluripotent Stem Cells (iPSCs) market and the competition landscape serves this objective. A wide company overview, financials, recent developments, and long and short-term strategies adopted are par for the course. Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in the sales of Induced Pluripotent Stem Cells (iPSCs) across the world has been calculated through primary and secondary research. The Induced Pluripotent Stem Cells (iPSCs) Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=222200&utm_source=NYH&utm_medium=888

Highlights of the Induced Pluripotent Stem Cells (iPSCs) market study:

Speculations for sales:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Induced Pluripotent Stem Cells (iPSCs) market. Additionally, it includes a share of every segment of the Induced Pluripotent Stem Cells (iPSCs) market, giving methodical information about types and applications of the market.

Key point summary of the Induced Pluripotent Stem Cells (iPSCs) market report:

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It presents an in-depth analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by creating a pin-point analysis of market segments and by having complete insights of the Induced Pluripotent Stem Cells (iPSCs) market.

This report helps users in comprehending the key product segments and their future.

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Induced Pluripotent Stem Cells (iPSCs) market

Chapter 2: Evaluating the leading manufacturers of the global Induced Pluripotent Stem Cells (iPSCs) market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Induced Pluripotent Stem Cells (iPSCs) market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Finally, the report global Induced Pluripotent Stem Cells (iPSCs) market describes Induced Pluripotent Stem Cells (iPSCs) industry expansion game plan, the Induced Pluripotent Stem Cells (iPSCs) industry knowledge supply, appendix, analysis findings and the conclusion. It includes a through explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Report customization:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Get Complete Report @ https://www.marketresearchintellect.com/need-customization/?rid=222200&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Induced Pluripotent Stem Cells (iPSCs) Market Size, Induced Pluripotent Stem Cells (iPSCs) Market Trends, Induced Pluripotent Stem Cells (iPSCs) Market Growth, Induced Pluripotent Stem Cells (iPSCs) Market Forecast, Induced Pluripotent Stem Cells (iPSCs) Market Analysis sarkari result, sarkari exam, sarkari naukri

Our Trending Reports

Next-Generation Batteries Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Nickel-Metal Hydride (Ni-MH) Battery Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Go here to see the original:
Induced Pluripotent Stem Cells (iPSCs) Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 - Cole of Duty

Induced Pluripotent Stem Cells Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026 – Weekly Wall

By adminMay 9, 2020Induced Pluripotent Stem Cells

Complete study of the global Covid-19 Impact on Induced Pluripotent Stem Cells market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Covid-19 Impact on Induced Pluripotent Stem Cells industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Covid-19 Impact on Induced Pluripotent Stem Cells production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Covid-19 Impact on Induced Pluripotent Stem Cells market include Fujifilm Holding Corporation, Astellas Pharma, Fate Therapeutics, Bristol-Myers Squibb Company, ViaCyte, Celgene Corporation, Aastrom Biosciences, Acelity Holdings, StemCells, Japan Tissue Engineering, Organogenesis, etc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1719097/covid-19-impact-on-induced-pluripotent-stem-cells-market

Segmental Analysis

The report has classified the global Covid-19 Impact on Induced Pluripotent Stem Cells industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Covid-19 Impact on Induced Pluripotent Stem Cells manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Covid-19 Impact on Induced Pluripotent Stem Cells industry.

Global Covid-19 Impact on Induced Pluripotent Stem Cells Market Segment By Type:

,Hepatocytes,Fibroblasts,Keratinocytes,Amniotic Cells,Others

Global Covid-19 Impact on Induced Pluripotent Stem Cells Market Segment By Application:

,Academic Research,Drug Development And Discovery,Toxicity Screening,Regenerative Medicine

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Covid-19 Impact on Induced Pluripotent Stem Cells industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key questions answered in the report:

Get Full Report in your inbox within 24 hours at 20% Discount: https://www.qyresearch.com/settlement/pre/d9ee06701c1798124a0199eca57151a6,0,1,covid-19-impact-on-induced-pluripotent-stem-cells-market

TOC

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Induced Pluripotent Stem Cells Industry1.7 COVID-19 Impact: Induced Pluripotent Stem Cells Market Trends 2 Global Induced Pluripotent Stem Cells Quarterly Market Size Analysis2.1 Induced Pluripotent Stem Cells Business Impact Assessment COVID-192.1.1 Global Induced Pluripotent Stem Cells Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Induced Pluripotent Stem Cells Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 By Players, Global Induced Pluripotent Stem Cells Quarterly Market Size, 2019 VS 20203.2 By Players, Induced Pluripotent Stem Cells Headquarters and Area Served3.3 Date of Key Players Enter into Induced Pluripotent Stem Cells Market3.4 Key Players Induced Pluripotent Stem Cells Product Offered3.5 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Induced Pluripotent Stem Cells Segments, By Type4.1 Introduction1.4.1 Hepatocytes1.4.2 Fibroblasts1.4.3 Keratinocytes1.4.4 Amniotic Cells1.4.5 Others4.2 By Type, Global Induced Pluripotent Stem Cells Market Size, 2019-2021 5 Impact of Covid-19 on Induced Pluripotent Stem Cells Segments, By Application5.1 Overview5.5.1 Academic Research5.5.2 Drug Development And Discovery5.5.3 Toxicity Screening5.5.4 Regenerative Medicine5.2 By Application, Global Induced Pluripotent Stem Cells Market Size, 2019-20215.2.1 By Application, Global Induced Pluripotent Stem Cells Market Size by Application, 2019-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 Fujifilm Holding Corporation7.1.1 Fujifilm Holding Corporation Business Overview7.1.2 Fujifilm Holding Corporation Induced Pluripotent Stem Cells Quarterly Revenue, 20207.1.3 Fujifilm Holding Corporation Induced Pluripotent Stem Cells Product Introduction7.1.4 Fujifilm Holding Corporation Response to COVID-19 and Related Developments7.2 Astellas Pharma7.2.1 Astellas Pharma Business Overview7.2.2 Astellas Pharma Induced Pluripotent Stem Cells Quarterly Revenue, 20207.2.3 Astellas Pharma Induced Pluripotent Stem Cells Product Introduction7.2.4 Astellas Pharma Response to COVID-19 and Related Developments7.3 Fate Therapeutics7.3.1 Fate Therapeutics Business Overview7.3.2 Fate Therapeutics Induced Pluripotent Stem Cells Quarterly Revenue, 20207.3.3 Fate Therapeutics Induced Pluripotent Stem Cells Product Introduction7.3.4 Fate Therapeutics Response to COVID-19 and Related Developments7.4 Bristol-Myers Squibb Company7.4.1 Bristol-Myers Squibb Company Business Overview7.4.2 Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Quarterly Revenue, 20207.4.3 Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Product Introduction7.4.4 Bristol-Myers Squibb Company Response to COVID-19 and Related Developments7.5 ViaCyte7.5.1 ViaCyte Business Overview7.5.2 ViaCyte Induced Pluripotent Stem Cells Quarterly Revenue, 20207.5.3 ViaCyte Induced Pluripotent Stem Cells Product Introduction7.5.4 ViaCyte Response to COVID-19 and Related Developments7.6 Celgene Corporation7.6.1 Celgene Corporation Business Overview7.6.2 Celgene Corporation Induced Pluripotent Stem Cells Quarterly Revenue, 20207.6.3 Celgene Corporation Induced Pluripotent Stem Cells Product Introduction7.6.4 Celgene Corporation Response to COVID-19 and Related Developments7.7 Aastrom Biosciences7.7.1 Aastrom Biosciences Business Overview7.7.2 Aastrom Biosciences Induced Pluripotent Stem Cells Quarterly Revenue, 20207.7.3 Aastrom Biosciences Induced Pluripotent Stem Cells Product Introduction7.7.4 Aastrom Biosciences Response to COVID-19 and Related Developments7.8 Acelity Holdings7.8.1 Acelity Holdings Business Overview7.8.2 Acelity Holdings Induced Pluripotent Stem Cells Quarterly Revenue, 20207.8.3 Acelity Holdings Induced Pluripotent Stem Cells Product Introduction7.8.4 Acelity Holdings Response to COVID-19 and Related Developments7.9 StemCells7.9.1 StemCells Business Overview7.9.2 StemCells Induced Pluripotent Stem Cells Quarterly Revenue, 20207.9.3 StemCells Induced Pluripotent Stem Cells Product Introduction7.9.4 StemCells Response to COVID-19 and Related Developments7.10 Japan Tissue Engineering7.10.1 Japan Tissue Engineering Business Overview7.10.2 Japan Tissue Engineering Induced Pluripotent Stem Cells Quarterly Revenue, 20207.10.3 Japan Tissue Engineering Induced Pluripotent Stem Cells Product Introduction7.10.4 Japan Tissue Engineering Response to COVID-19 and Related Developments7.11 Organogenesis7.11.1 Organogenesis Business Overview7.11.2 Organogenesis Induced Pluripotent Stem Cells Quarterly Revenue, 20207.11.3 Organogenesis Induced Pluripotent Stem Cells Product Introduction7.11.4 Organogenesis Response to COVID-19 and Related Developments 8 Key Findings 9 Appendix9.1 About US9.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Go here to see the original:
Induced Pluripotent Stem Cells Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026 - Weekly Wall

Sumit Dewanjee, MD, is being recognized by Continental Who’s Who – PRNewswire

By adminMay 7, 2020Stem Cell Medical Center

TEMPE, Ariz., May 7, 2020 /PRNewswire/ --Sumit Dewanjee, MD, is being recognized by Continental Who's Who as a Top Orthopedic Surgeon in the field of medicine as an at FXRX Orthopedics and Bracing.

Serving patients in the metropolitan Phoenix, Arizona area FXRX is the leading practice in Arizona for orthopedic surgery. FXRX mainly focuses on orthopedic sports injuries of the hip, knee, and shoulder, along with orthopedic fracture treatments such as stem cell therapy and cartilage restoration procedures.

Dr. Sumit Dewanjee is the founder and premier Board-certified Orthopedic Surgeon at FXRX with 16 years' experience in orthopedic surgery. His particular areas of focus are knee and shoulder surgery, fracture treatment and he's knowledgeable in both general orthopedics and orthopedic bracing. His additional skills include performing minimally invasive procedures using arthroscopy, with expertise in minimizing blood loss and patient recovery periods while providing the results and benefits of advanced and cutting edge treatments in surgery.

To gain the knowledge needed for his successful career with his private practice, Dr. Dewanjee attended the University of Miami and received his Medical Degree followed by Maricopa Medical Center to complete his residency.

In addition to his affiliations with MENSA, American Academy Ortho Surgeons, Dr. Dewanjee has been awarded the Patient Choice Award for the 7th time, maintaining his status as one of the best orthopedic surgeons in Phoenix, AZ. and Compassionate Doctors.

During his free time, Dr. Dewanjee donates to The Human Society.

Dr. Dewanjee dedicates his success to his mentor Dr. Dana Seltzer.

For more information please visit fxrxinc.com

Contact: Katherine Green , 516-825-5634 [emailprotected]

SOURCE Continental Who's Who

http://www.continentalwhoswho.com

Excerpt from:
Sumit Dewanjee, MD, is being recognized by Continental Who's Who - PRNewswire

Results From Pivotal Phase 2/3 Study of Emapalumab in Patients With Primary HLH Published in New England Journal of Medicine – BioSpace

By adminMay 7, 2020Stem Cell Medical Center

STOCKHOLM, May 7, 2020 /PRNewswire/ -- Sobi announced today that the results from the pivotal phase 2/3 study evaluating the efficacy and safety of emapalumab in patients with primary haemophagocytic lymphohistiocytosis (HLH) were published in the New England Journal of Medicine on 7 May 2020. Emapalumab is the first therapy approved by the US Food & Drug Administration (FDA) for primary HLH and is under review by the European Medicines Agency (EMA).

Primary HLH is a rare syndrome that typically presents in infancy but can also be seen in adults and is associated with high morbidity and mortality. This life-threatening disease is characterised by immune dysregulation and uncontrolled hyperinflammation. The treatment objective is to suppress the hyperinflammation and control the acute features of the disease in order to successfully bring patients to haematopoietic stem cell transplantation (HSCT).

"The publication of the results in this highly respected medical journal is a testament to the medical importance of the emapalumab findings for patients with primary HLH," says Milan Zdravkovic, Head of Research & Development and Chief Medical Officer at Sobi. "The results further advance our understanding of primary HLH and the role of interferon gamma in its pathogenesis. Our hope is to contribute to the improvement of care and treatment for patients suffering from this potentially fatal disease."

The results with emapalumab in primary HLH published in the New England Journal of Medicine highlight the overall response rate of 63 percent in previously treated patients at the end of up to 8 weeks of treatment (compared to the pre-specified null hypothesis of 40 percent (p=0.02)). In the previously treated group, 70 percent of patients were able to proceed to transplantation. The most commonly reported adverse reactions ( 20 per cent) were infections, hypertension, infusion-related reactions and fever.

Michael Jordan, Professor of Pediatrics at the Cincinnati Children's Hospital Medical Center in the US and coordinating Principal Investigator of the study (US), confirms the importance of making advances in finding new therapies for HLH and emphasises the importance of the publication of the results: "The findings from the study are encouraging for those affected by this devastating disease."

Professor Franco Locatelli, Head of the Department of Onco-Haematology, Bambino Ges Children's Hospital IRCCS, Sapienza University of Rome, Italy, and coordinating Principal Investigator (EU), adds: "Emapalumab represents a prototype model molecularly targeted therapy and an important step towards improving outcomes for this severe and life-threatening disease."

This pivotal clinical study is the first study in primary HLH to prospectively assess and report treatment responses using predefined comprehensive objective clinical and laboratory criteria. Preclinical data have shown the central role of interferon gamma (IFN) in the pathogenesis of this disease1. Emapalumab is a monoclonal antibody that binds to and neutralises IFN. It was approved by the US Food & Drug Administration (FDA) on the basis of this clinical study for the treatment of primary HLH in adult and paediatric (newborn and older) patients with refractory, recurrent or progressive disease, or intolerance to conventional HLH therapy, and received Breakthrough Designation prior to review.

About emapalumab

Emapalumab is a monoclonal antibody that binds to and neutralises interferon gamma (IFN). In the US, emapalumab is indicated for paediatric (newborn and older) and adult primary haemophagocytic lymphohistiocytosis (HLH) patients with refractory, recurrent or progressive disease, or intolerance to conventional HLH therapy. Emapalumab is the first and only medicine approved in the US for primary HLH, a rare syndrome of hyperinflammation that usually occurs within the first year of life and can rapidly become fatal unless diagnosed and treated. The FDA approval is based on data from the phase 2/3 studies (NCT01818492 and NCT02069899). Emapalumab is indicated for administration through intravenous infusion over one hour twice per week until haematopoietic stem cell transplantation (HSCT). For more information please see http://www.gamifant.com including the full US Prescribing Information. Emapalumab is under review for primary HLH by the European Medicines Agency (EMA).

About SobiTM

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,400 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi's revenues amounted to SEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

For more information please contactPaula Treutiger, Head of Communication & Investor Relations+ 46-733-666-599paula.treutiger@sobi.com

Linda Holmstrm,Corporate Communication & Investor Relations+46-708-734-095linda.holmstrom@sobi.com

1. Jordan et al. Blood 2004;104:735-43.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/results-from-pivotal-phase-2-3-study-of-emapalumab-in-patients-with-primary-hlh-published-in-new-eng,c3105820

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/results-from-pivotal-phase-23-study-of-emapalumab-in-patients-with-primary-hlh-published-in-new-england-journal-of-medicine-301054583.html

SOURCE Swedish Orphan Biovitrum AB

Company Codes: Berlin:B6E, Bloomberg:SOBI@SS, ISIN:SE0000872095, LSE:0MTD, OTC-PINK:BIOVF, RICS:SOBI.ST, Stockholm:SOBI, Dusseldorf:B6E, Frankfurt:B6E, Stuttgart:B6E

COVID-19 Impact and Recovery Analysis | Global Cell Isolation Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and Becton,…

By adminMay 7, 2020Stem Cell Medical Center

LONDON--(BUSINESS WIRE)--The global cell isolation market size is expected to grow by USD 9.47 billion as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. Moreover, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of almost 21%.

Request for Technavio's latest reports on directly and indirectly impacted markets

Market estimates include pre- and post-COVID-19 impact on the cell isolation market -

Download free sample report

With the spread of COVID-19, a global increase in R&D activities in AR and PB has been observed in the first half of 2020. Researches are being conducted on stem cell therapies to develop mesenchymal stem cell-based therapies. For instance, in March 2020, researchers from the University of North Texas Health Science Center initiated a clinical trial in China on more than 100 COVID-19 patients and administered injections of mesenchymal stem cells. The rise in such R&D activities is increasing the demand for cell isolation products, which will result in the growth of the cell isolation market during the forecast period.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

https://www.technavio.com/report/global-cell-isolation-market-industry-analysis

The market is driven by the increasing prevalence of chronic diseases. In addition, product advances are anticipated to boost the growth of the cell isolation market.

With the growing incidence of chronic diseases globally, the applications of isolated human cells in research, drug development, and clinical trials are increasing. Cell isolation helps study the behavior of cells and their response to diseases and different drugs. Cell isolation tools are used in drug discovery to generate recombinant protein therapeutics, which can treat a variety of chronic diseases. Hence, the rising prevalence of chronic diseases will boost the need for cell-based therapies, which, in turn, will increase the demand for cell isolation tools.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Cell Isolation Companies:

Agilent Technologies Inc.

Agilent Technologies Inc. has business operations under various segments, such as life sciences and applied markets, diagnostics and genomics, and Agilient CrossLab. The company offers various consumables and instruments for cell isolation procedures.

Becton, Dickinson and Co.

Becton, Dickinson and Co. operates its business through various segments, such as BD Medical, BD Life Sciences, and BD Interventional. The company provides consumables and instruments for cell isolation procedures.

Bio-Rad Laboratories Inc.

Bio-Rad Laboratories Inc. has business operations under two segments: life science and clinical diagnostics. The company provides consumables and instruments for cell isolation procedures.

Danaher Corp.

Danaher Corp. operates its business through various segments, such as life sciences, diagnostics, and environment & applied solutions. The company provides consumables and instruments for cell isolation procedures.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. has business operations under two segments: pharmaceuticals and diagnostics. The company provides consumables and instruments for cell isolation procedures.

Technavio's SUBSCRIPTION platform

Cell Isolation Market Product Outlook (Revenue, USD bn, 2020-2024)

Cell Isolation Market Geography Outlook (Revenue, USD bn, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View post:
COVID-19 Impact and Recovery Analysis | Global Cell Isolation Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and Becton,...

Stem Cell Alopecia Treatment Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026 – 3rd Watch News

By adminMay 7, 2020Stem Cell Medical Center

Stem Cell Alopecia Treatment Market Trends, Size, Shares, Growth, Top Companies, Development, Application, Importance, Overview with Detailed Analysis, Production, Supply, Revenue, Regional Outlook, Status, Competitive Landscape, Future Forecast, Type and End-User, Opportunity, Demand, Historical Data, Business Insights, Research Methodology and many more

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Stem Cell Alopecia Treatment Market which would mention How the Covid-19 is Affecting the Stem Cell Alopecia Treatment Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Stem Cell Alopecia Treatment Players to Combat Covid-19 Impact.

Stem Cell Alopecia Treatment research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers, and challenges.

Top Key Players of the Global Stem Cell Alopecia Treatment Market:APEX Biologix, Belgravia Center, Kerastem, Riken Research Institute, RepliCel, Sanford Burnham Prebys Medical Discovery Institute,

Download Full PDF Sample Copy of Stem Cell Alopecia Treatment Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.qyresearch.com/sample-form/form/1491764/global-stem-cell-alopecia-treatment-market

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

Global Stem Cell Alopecia Treatment Market is estimated to reach xxx million USD in 2019 and projected to grow at the CAGR of xx% during 2019-2025. According to the latest report added to the online repository of QY Research the Stem Cell Alopecia Treatment market has witnessed an unprecedented growth till 2019. The extrapolated future growth is expected to continue at higher rates by 2025.

Stem Cell Alopecia Treatment Market Size Estimation

Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).

The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.

Get Full Customize report now at: https://www.qyresearch.com/customize-request/form/1491764/global-stem-cell-alopecia-treatment-market

Critical questions addressed by the Stem Cell Alopecia Treatment Market report

What are the key market drivers and restraints?What will be the market size until the end of the forecast period?Which segment is expected to take the lions share?Which region will lead the global Stem Cell Alopecia Treatment market in terms of growth?What will be the key strategies adopted by market leaders in future?What are the upcoming applications?How will the global Stem Cell Alopecia Treatment market develop in the mid to long term?

Table of Contents

1 Stem Cell Alopecia Treatment Market Overview1.1 Stem Cell Alopecia Treatment Product Overview1.2 Stem Cell Alopecia Treatment Market Segment by Type1.2.1 Cloud Service Orchestration1.2.2 API Management1.2.3 Application Integration1.2.4 B2B and Cloud Integration1.2.5 Data Integration1.3 Global Stem Cell Alopecia Treatment Market Size by Type1.3.1 Global Stem Cell Alopecia Treatment Sales and Growth by Type1.3.2 Global Stem Cell Alopecia Treatment Sales and Market Share by Type (2014-2019)1.3.3 Global Stem Cell Alopecia Treatment Revenue and Market Share by Type (2014-2019)1.3.4 Global Stem Cell Alopecia Treatment Price by Type (2014-2019)

2 Global Stem Cell Alopecia Treatment Market Competition by Company2.1 Global Stem Cell Alopecia Treatment Sales and Market Share by Company (2014-2019)2.2 Global Stem Cell Alopecia Treatment Revenue and Share by Company (2014-2019)2.3 Global Stem Cell Alopecia Treatment Price by Company (2014-2019)2.4 Global Top Players Stem Cell Alopecia Treatment Manufacturing Base Distribution, Sales Area, Product Types2.5 Stem Cell Alopecia Treatment Market Competitive Situation and Trends2.5.1 Stem Cell Alopecia Treatment Market Concentration Rate2.5.2 Global Stem Cell Alopecia Treatment Market Share of Top 5 and Top 10 Players2.5.3 Mergers & Acquisitions, Expansion

3 Stem Cell Alopecia Treatment Company Profiles and Sales Data3.1 IBM3.1.1 Company Basic Information, Manufacturing Base and Competitors3.1.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.1.3 IBM Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.1.4 Main Business Overview3.2 Microsoft3.2.1 Company Basic Information, Manufacturing Base and Competitors3.2.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.2.3 Microsoft Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.2.4 Main Business Overview3.3 Oracle3.3.1 Company Basic Information, Manufacturing Base and Competitors3.3.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.3.3 Oracle Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.3.4 Main Business Overview3.4 Software3.4.1 Company Basic Information, Manufacturing Base and Competitors3.4.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.4.3 Software Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.4.4 Main Business Overview3.5 TIBCO Software3.5.1 Company Basic Information, Manufacturing Base and Competitors3.5.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.5.3 TIBCO Software Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.5.4 Main Business Overview3.6 Accenture3.6.1 Company Basic Information, Manufacturing Base and Competitors3.6.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.6.3 Accenture Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.6.4 Main Business Overview3.7 Adeptia3.7.1 Company Basic Information, Manufacturing Base and Competitors3.7.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.7.3 Adeptia Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.7.4 Main Business Overview3.8 Atos3.8.1 Company Basic Information, Manufacturing Base and Competitors3.8.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.8.3 Atos Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.8.4 Main Business Overview3.9 Axway3.9.1 Company Basic Information, Manufacturing Base and Competitors3.9.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.9.3 Axway Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.9.4 Main Business Overview3.10 BT Global Services3.10.1 Company Basic Information, Manufacturing Base and Competitors3.10.2 Stem Cell Alopecia Treatment Product Category, Application and Specification3.10.3 BT Global Services Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin(2014-2019)3.10.4 Main Business Overview

4 Stem Cell Alopecia Treatment Market Status and Outlook by Regions4.1 Global Market Status and Outlook by Regions4.1.1 Global Stem Cell Alopecia Treatment Market Size and CAGR by Regions4.1.2 North America4.1.3 Asia-Pacific4.1.4 Europe4.1.5 South America4.1.6 Middle East and Africa4.2 Global Stem Cell Alopecia Treatment Sales and Revenue by Regions4.2.1 Global Stem Cell Alopecia Treatment Sales and Market Share by Regions (2014-2019)4.2.2 Global Stem Cell Alopecia Treatment Revenue and Market Share by Regions (2014-2019)4.2.3 Global Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin (2014-2019)4.3 North America Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin4.3.1 United States4.3.2 Canada4.3.3 Mexico4.4 Europe Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin4.4.1 Germany4.4.2 UK4.4.3 France4.4.4 Italy4.4.5 Russia4.4.6 Turkey4.5 Asia-Pacific Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin4.5.1 China4.5.2 Japan4.5.3 Korea4.5.4 Southeast Asia4.5.4.1 Indonesia4.5.4.2 Thailand4.5.4.3 Malaysia4.5.4.4 Philippines4.5.4.5 Vietnam4.5.5 India4.5.6 Australia4.6 South America Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin4.6.1 Brazil4.7 Middle East and Africa Stem Cell Alopecia Treatment Sales, Revenue, Price and Gross Margin4.7.1 Egypt4.7.2 GCC Countries

5 Stem Cell Alopecia Treatment Application/End Users5.1 Stem Cell Alopecia Treatment Segment by Application5.1.1 Banking, Financial Services, and Insurance5.1.2 Consumer Goods and Retail5.1.3 Education5.1.4 Government and Public Sector5.1.5 Healthcare and Life Sciences5.1.6 Manufacturing5.1.7 Media and Entertainment5.1.8 Telecommunication and Ites5.1.9 Others5.2 Global Stem Cell Alopecia Treatment Product Segment by Application5.2.1 Global Stem Cell Alopecia Treatment Sales by Application5.2.2 Global Stem Cell Alopecia Treatment Sales and Market Share by Application (2014-2019)

6 Global Stem Cell Alopecia Treatment Market Forecast6.1 Global Stem Cell Alopecia Treatment Sales, Revenue Forecast (2019-2025)6.1.1 Global Stem Cell Alopecia Treatment Sales and Growth Rate Forecast (2019-2025)6.1.1 Global Stem Cell Alopecia Treatment Revenue and Growth Rate Forecast (2019-2025)6.2 Global Stem Cell Alopecia Treatment Forecast by Regions6.2.1 North America Stem Cell Alopecia Treatment Sales and Revenue Forecast (2019-2025)6.2.2 Europe Stem Cell Alopecia Treatment Sales and Revenue Forecast (2019-2025)6.2.3 Asia-Pacific Stem Cell Alopecia Treatment Sales and Revenue Forecast (2019-2025)6.2.3.1 China6.2.3.2 Japan6.2.3.3 Korea6.2.3.4 Southeast Asia6.2.3.5 India6.2.3.6 Australia6.2.4 South America Stem Cell Alopecia Treatment Sales and Revenue Forecast (2019-2025)6.2.5 Middle East and Africa Stem Cell Alopecia Treatment Sales and Revenue Forecast (2019-2025)6.2.5.1 Egypt6.2.5.2 GCC Countries6.3 Stem Cell Alopecia Treatment Forecast by Type6.3.1 Global Stem Cell Alopecia Treatment Sales and Revenue Forecast by Type (2019-2025)6.3.2 Cloud Service Orchestration Gowth Forecast6.3.3 API Management Gowth Forecast6.4 Stem Cell Alopecia Treatment Forecast by Application6.4.1 Global Stem Cell Alopecia Treatment Sales Forecast by Application (2019-2025)6.4.2 Global Stem Cell Alopecia Treatment Forecast in Banking, Financial Services, and Insurance6.4.3 Global Stem Cell Alopecia Treatment Forecast in Consumer Goods and Retail

7 Stem Cell Alopecia Treatment Upstream Raw Materials7.1 Stem Cell Alopecia Treatment Key Raw Materials7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price7.1.3 Raw Materials Key Suppliers7.2 Manufacturing Cost Structure7.2.1 Raw Materials7.2.2 Labor Cost7.2.3 Manufacturing Expenses7.3 Stem Cell Alopecia Treatment Industrial Chain Analysis

8 Marketing Strategy Analysis, Distributors8.1 Marketing Channel8.1.1 Direct Marketing8.1.2 Indirect Marketing8.1.3 Marketing Channel Development Trend8.2 Distributors8.3 Downstream Customers

9 Research Findings and Conclusion

AppendixMethodology/Research ApproachResearch Programs/DesignMarket Size EstimationMarket Breakdown and Data TriangulationData SourceSecondary SourcesPrimary SourcesDisclaimer

About Us:

Originally posted here:
Stem Cell Alopecia Treatment Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026 - 3rd Watch News

BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn for The European Union – BioSpace

By adminMay 7, 2020Adult Stem Cells

NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today a lease agreement with the Tel Aviv Sourasky Medical Center (Sourasky) in Tel Aviv, Israel, to produce NurOwn in three state-of-the-art cleanrooms. The new facility will significantly increase the Companys capacity to manufacture and ship its product into the European Union and the local Israeli market. The cleanroom facility is part of Souraskys Institute for Advanced Cellular Therapies.

"Sourasky Hospital is a leader in the advancement and manufacturing of cell and gene therapy products and is well-equipped to rapidly scale up and produce NurOwn," stated Prof. Ronni Gamzu, CEO of Tel Aviv Sourasky Medical Center. "We look forward to continuing our work with BrainStorm to bring NurOwn to ALS patients and help fulfill the clinical therapy demands for the Companys pipeline programs.

"Sourasky Hospital, known for introducing pioneering solutions into clinical practice and advancing patient care, has a first rate team with the proven experience to produce regenerative products in accordance to the highest standard of cGMP manufacturing," said Chaim Lebovits, CEO of BrainStorm. "This agreement will ensure that we can provide NurOwn to patients after regulatory approval, not only in Israel but we have secured capacity to rapidly scale up production as we advance our investigational treatment across the European Union. We are very pleased to be able to expand our ongoing collaboration with Sourasky Hospital, one of the worlds most innovative and respected medical centers."

About NurOwn NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company's website at http://www.brainstorm-cell.com

Safe-Harbor Statement Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: + 1.862.397.1860pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

See the rest here:
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn for The European Union - BioSpace